Raising awareness for the sarcoma cancer chordoma.

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 172 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
H. RES. 172

           Raising awareness for the sarcoma cancer chordoma.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 27, 2025

    Mr. Johnson of Georgia (for himself, Mrs. McBath, Ms. Wilson of 
    Florida, Ms. Velazquez, and Ms. Norton) submitted the following 
 resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
           Raising awareness for the sarcoma cancer chordoma.

Whereas chordoma is a slow growing, yet aggressive bone cancer of the skull and 
        spine;
Whereas it strikes people of all ages and affects more than 25,000 individuals 
        worldwide;
Whereas, each year, thousands of people are diagnosed with chordoma including 
        about 300 people annually in the United States;
Whereas chordomas are among the most complicated tumors to treat due to 
        involvement of critical structures such as the brain stem, spinal cord, 
        and important nerves and arteries;
Whereas surgery or radiation performed by a skilled treatment team can be 
        curative for some patients, but even with the best care possible, the 
        recurrence rate remains high; and
Whereas no drugs are known to cure or effectively control the disease, meaning 
        that patients whose disease progresses after exhausting surgical and 
        radiation options have little hope for a full recovery: Now, therefore, 
        be it
    Resolved, That it is the sense of the House of Representatives that 
chordoma patients and families need increased funding and support for--
            (1) accurate and early diagnosis;
            (2) the development of new treatments, diagnostics, and 
        cures;
            (3) fewer hurdles between research and new treatments; and
            (4) patient-centric approaches to drug discovery and 
        development.
                                 <all>